Sintilimab plus bevacizumab biosimilar IBI305 and chemotherapy for patients with EGFR-mutated non-squamous non-small-cell lung cancer who progressed on EGFR tyrosine-kinase inhibitor therapy (ORIENT-31): first interim results from a randomised, double-blind, multicentre, phase 3 trial

• Published in: The lancet oncology Vol. 23; no. 9; pp. 1167 - 1179
• Main Authors: Lu, Shun, Wu, Lin, Jian, Hong, Chen, Ying, Wang, Qiming, Fang, Jian, Wang, Ziping, Hu, Yanping, Sun, Meili, Han, Liang, Miao, Liyun, Ding, Cuimin, Cui, Jiuwei, Li, Baolan, Pan, Yueyin, Li, Xingya, Ye, Feng, Liu, Anwen, Wang, Ke, Cang, Shundong, Zhou, Hui, Sun, Xing, Ferry, David, Lin, Yong, Wang, Shuyan, Zhang, Wen, Zhang, Chengli
• Format: Journal Article
• Language: English
• Published: London Elsevier Ltd 01.09.2022; Elsevier Limited
• Subjects: Bevacizumab; Biological products; Brain cancer; Cancer therapies; Chemotherapy; Cisplatin; Double-blind studies; Enzyme inhibitors; Epidermal growth factor receptors; Hematology, Oncology, and Palliative Medicine; Hemorrhage; Histology; Immunotherapy; Leukocytes (neutrophilic); Life span; Lung cancer; Medical prognosis; Metastases; Metastasis; Monoclonal antibodies; Mutation; Myelosuppression; Non-small cell lung carcinoma; Patients; Small cell lung carcinoma; Targeted cancer therapy; Translation; Treatment resistance; Tumors; Vascular endothelial growth factor; United States > US; China

VEGF inhibitors can enhance the efficacy of immunotherapy. However, despite high initial response rates, almost all patients eventually develop treatment resistance to EGFR tyrosine-kinase inhibitors. We aimed to evaluate the efficacy and safety of sintilimab with or without IBI305 plus pemetrexed a...